Topical Hormonal Acne Treatments in a 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne

A 2026 review finds clascoterone 1% cream has the strongest trial support among topical hormonal acne treatments for adults with persistent acne, but success rates were modest and follow-up was short. Topical hormonal treatment means a cream or solution applied to skin that blocks male-hormone signals that raise oil and inflammation. Adult persistent acne means pimples present most days after age 25 without clear acne-free periods. It affects mainly women, often leaves scarring and dark marks, and needs options that work long term without strong whole-body effects.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Who has adult persistent acne?
What did the best clascoterone trials test?
How well did clascoterone work?
Why is topical spironolactone evidence still weak?
What can adults do next?

Who has adult persistent acne?

Adult persistent acne is acne that continues from the teens or returns and stays after age 25. It makes up about 80% of adult female acne, with 14-20% prevalence in adult women.

Breakouts often sit on the lower face, jaw, chin, and neck. Many patients have oily skin, monthly flares, clogged pores plus red painful bumps, and leftover marks after spots fade.

What did the best clascoterone trials test?

Clascoterone 1% cream, sold as Winlevi, is a first-in-class topical androgen-receptor inhibitor for acne in patients 12 years and older. It blocks hormone receptors in oil glands and hair follicles to lower oil and inflammation, according to the FDA approval letter. The two identical Phase 3 trials, CB-03-01/25 and CB-03-01/26, enrolled 1,440 patients with moderate-to-severe facial acne.

Patients applied about 1 g of cream or vehicle twice daily to the whole face for 12 weeks. That design tests whole-face use, not spot treatment. Twice-daily use for 12 weeks sets a clear bar for judging response, irritation, and daily fit.

How well did clascoterone work?

At week 12, treatment success meant clear or almost clear skin plus at least a two-grade improvement. Success was 18.4% versus 9.0% in one trial and 20.3% versus 6.5% in the other, with greater drops in red bumps and clogged pores, as summarized by Skin Therapy Letter. Those numbers show a real edge over vehicle, but most patients did not reach clear or almost clear.

Benefits must be weighed against daily routine, skin dryness or burning, and continued use to hold gains. The American Academy of Dermatology 2024 guidelines rate the evidence certainty as high yet give only a conditional recommendation because high cost may limit fair access, as reported by Managed Healthcare Executive. Ask about insurance coverage, prior approval rules, and refill cost before starting. Cost can decide whether a modest average benefit is worth it for you.

Why is topical spironolactone evidence still weak?

Topical spironolactone has no strong large-trial base for acne. One often-cited example used 2% solution twice daily for 12 weeks in only 35 adults versus clindamycin. Systematic reviews rate this evidence as low to very low because samples are tiny and results are imprecise, according to the 2025 hormonal-therapies update in Dermatology and Therapy.

Prior reviews noted the largest randomized spironolactone acne trial had only 34 patients. That gap led researchers to run the 398-patient SAFA Phase 3 trial of oral spironolactone plus usual topical care in women. For topical use, readers should treat claims about strength, dosing, and safety as early and unsettled.

What can adults do next?

Use trial design to guide a clinic visit. Bring your acne history, cycle-related flares, past topicals, and photos of good and bad weeks.

Clascoterone showed placebo-like whole-body safety in trials plus a 9-month open-label extension, with mainly mild burning or redness and no need for potassium checks used with oral spironolactone. Keep routine gentle, avoid picking, and track scarring or dark marks early because they guide follow-up care.

Ask whether you fit the tested group: moderate-to-severe facial acne treated across the whole face
Ask how to judge 12-week response: lesion counts, photos, and a clear or almost-clear goal
Ask about local effects: burning, redness, dryness, and when to pause or adjust
Ask about cost and access: coverage, refills, and backup topical plan if cost blocks use